Purpose of Review <p>Lipoprotein(a) [Lp(a)] is an increasingly recognized, genetically determined contributor to cardiovascular risk, implicated in both atherosclerotic cardiovascular disease and aortic valve stenosis. At present, several emerging therapies specifically targeting Lp(a) are under development.</p> Recent Findings <p>Given the high prevalence of elevated Lp(a) levels in the general population, major cardiovascular societies now recommend at least one lifetime measurement in all high risk adults. While no approved treatments currently exist, several novel Lp(a) lowering therapies are in advanced stages of clinical development and show considerable promise.</p> Summary <p>This review outlines the biological and genetic basis of Lp(a), examines itsassociation with diverse cardiovascular diseases, and highlights emergingtherapeutic strategies that may significantly influence future clinical management.</p>